In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioVentrix Inc.

Minimally invasive and non-surgical treatments for HF

This article was originally published in Start Up

Executive Summary

The most prevalent kind of heart failure is caused by heart attack damage to the left ventricle, and the standard treatment is an open-heart procedure called surgical ventricular restoration. BioVentrix Inc. aims to replace SVR with a less invasive version of the procedure, using its Revivent Myocardial Anchoring System, designed to pull the damaged segments of the left ventricle together to reduce the burden on the non-damaged myocardium and improve its performance.



Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts